Alcon (ALC)
(Delayed Data from NYSE)
$92.38 USD
-1.44 (-1.53%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $92.40 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALC 92.38 -1.44(-1.53%)
Will ALC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALC
Here's Why Alcon (ALC) is a Strong Momentum Stock
Here's Why Alcon (ALC) is a Strong Momentum Stock
ALC: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific
Alcon (ALC) Rides on Innovation, Balanced Segmental Sales
Buy 5 Medical Devices Stocks to Enhance Your Portfolio in 2H
Other News for ALC
Evolus Continues To Make Progress
Algoma Central Corporation Reports Financial Results for the 2024 Second Quarter
Algoma Central Braces for Growth Despite Challenges
Alcon: Trading At An Undeserved Premium Valuation
Alcidion Reports Record Cash Receipts in Q4 FY24